Clinical trials · Washington, D.C., DC
Allergy clinical trials in Washington, D.C.
We’re tracking 139 recruiting allergy studies with a site in or near Washington, D.C. — including Phase 1, Phase 1/Phase 2 and Phase 2 studies, each written for real people, not researchers.
Recruiting studies near Washington, D.C.
- NCT04653324Recruiting
Registry for people with diagnosed food allergies
This registry aims to collect information from people who already have a diagnosed food allergy. Joining may help researchers better understand food allergy patterns and needs.
McLean, VirginiaAges Any age - NCT07046806RecruitingPhase 1/Phase 2
Oral deucrictibant for hereditary angioedema attacks
This trial tests an oral medication called deucrictibant to prevent and treat swelling attacks in people with hereditary angioedema. It may help reduce the number and severity of attacks.
Wheaton, MarylandAges 18–75 - NCT04582903Recruiting
Send-in sample collection study for immune response to respiratory viruses
This study collects sent-in samples to better understand how your immune system responds during a COVID-19–like illness and after you recover. It may help researchers learn why some people get sick and others stay uninfected, and how immune protection works over time.
Rockville, MarylandAges 1 day–99 years - NCT07108387RecruitingPhase 2
Stopping or reducing tocilizumab for well-controlled giant cell arteritis
This study compares stopping tocilizumab (Actemra) completely versus reducing the dose in people whose giant cell arteritis has been well controlled for at least a year. The goal is to find out which approach keeps the disease in remission while reducing medication side effects.
Baltimore, MarylandAges 50 years+ - NCT07103746RecruitingPhase 2
Ublituximab for antibody-positive IMNM
This study tests an investigational medication called ublituximab (an infusion) for people with a rare autoimmune muscle disease called IMNM. It aims to reduce muscle weakness and damage by targeting specific immune cells (B cells). To join, you need a recent diagnosis (within 1 year), specific antibodies, and be on limited other medications.
Baltimore, MarylandAges 18 years+ - NCT07059091RecruitingPhase 2
Omalizumab for COPD with allergies
This trial tests if omalizumab, an allergy medication, can help people with COPD who have allergies to common indoor triggers like cat, dog, mouse, cockroach, or dust mite. It aims to reduce flare-ups and improve breathing.
Baltimore, MarylandAges 40 years+ - NCT05671757RecruitingPhase 1/Phase 2
Daratumumab for primary antiphospholipid syndrome
This early-phase study tests daratumumab, an immune-targeting drug, for people with primary antiphospholipid syndrome (APS). It aims to see whether it can reduce APS activity and improve outcomes while you continue your usual blood-thinning treatment.
Baltimore, MarylandAges 18–65 - NCT06517693RecruitingPhase 1
HIV antibody safety study for newborns at risk
This study tests whether giving a combination of two lab-made antibodies (PGT121.414.LS and VRC07-523LS) to newborns exposed to HIV during pregnancy is safe and how the body processes them. It may help protect infants from getting HIV after birth.
Baltimore, MarylandAges Up to 3 days - NCT07110532RecruitingPhase 1
A study of flu virus exposure in healthy adults
This trial tests how the body reacts to a specific flu virus (pH1N1) in a controlled setting. Healthy volunteers are exposed to the virus to help researchers understand the infection and test treatments. You will be monitored closely and given antiviral medication if needed.
Baltimore, MarylandAges 18–55 - NCT07536308RecruitingPhase 1
Nasal COVID-19 booster vaccine safety trial
This trial tests a new nasal spray COVID-19 booster vaccine. It aims to see if the vaccine is safe and produces a strong immune response when given through the nose and inhaled, in people who have already been vaccinated.
Baltimore, MarylandAges 18–64 - NCT06075745RecruitingPhase 2
CMV Vaccine Study for Liver Transplant Candidates
This trial tests a vaccine to prevent cytomegalovirus (CMV) infection in people awaiting a first liver transplant. You may be eligible if you have never been infected with CMV and are scheduled to receive a liver transplant within the next 1 to 12 months.
Baltimore, MarylandAges 18 years+ - NCT06476132RecruitingPhase 2
Belumosudil for lung transplant patients at risk of chronic rejection
This trial tests whether the drug Belumosudil can help prevent chronic lung rejection in people who recently had a lung transplant and showed signs of early rejection. It may improve long-term lung health.
Baltimore, MarylandAges 12 years+ - NCT07040319RecruitingPhase 1/Phase 2
Hepatitis C treatment study for pregnant women
This study tests a medicine called glecaprevir/pibrentasvir for pregnant women with hepatitis C, with or without HIV. It aims to see how the medicine works in the body and if it is safe during pregnancy.
Baltimore, MarylandAges 16–45 - NCT02140255RecruitingPhase 1/Phase 2
Intensive early HIV treatment in newborns to aim for remission
This study gives very early, intensive HIV medicine to infants diagnosed with HIV and follows them closely to see if HIV can go into remission (stop being detectable without ongoing treatment). It may help families understand whether treating right after birth can change a child’s long-term HIV outlook.
Baltimore, MarylandAges Up to 2 days - NCT07015996RecruitingPhase 2
Tezepelumab for peanut allergy oral immunotherapy
This trial tests whether adding tezepelumab (a biologic drug) to peanut oral immunotherapy can help people with peanut allergy better tolerate small amounts of peanut protein without having an allergic reaction.
Baltimore, MarylandAges 12–55 - NCT07778459Recruiting
Liver transplant study for people with HIV
This study tests whether it's safe and effective for people with HIV to receive a liver transplant from a donor who also has HIV. It aims to expand access to transplants for people with HIV.
Baltimore, MarylandAges 18 years+ - NCT06033196RecruitingPhase 2
Tocilizumab to prevent lung transplant rejection
This trial tests a drug called tocilizumab (brand name Actemra) to see if it helps prevent rejection after lung transplantation. Tocilizumab targets part of the immune system that may otherwise attack the new lungs.
Baltimore, MarylandAges 12–75 - NCT06934200RecruitingPhase 2
Xolair for food allergy in people with high IgE
This study tests if omalizumab (Xolair), an injectable medicine that blocks allergy antibodies, can help people with food allergies tolerate small amounts of their trigger foods. It's for people with high total IgE levels who were not eligible for a related study.
Baltimore, MarylandAges 1–55 - NCT05917522RecruitingPhase 2
Biomarker-guided changes to anti-rejection medicines after kidney transplant
This Phase 2 study looks at whether blood test “biomarkers” can guide safely changing anti-rejection medicines after an ABO-compatible kidney transplant. It may help some people reduce certain medicines while keeping the new kidney protected from rejection.
Baltimore, MarylandAges 18–70
Hear when a new Allergy trial opens near Washington, D.C., DC
We’ll email you when one opens near Washington, D.C., DC — at most once a week, no account needed, unsubscribe anytime.
Allergy trials in other cities
Where these studies are running near Washington, D.C.
Institutions with a site for the recruiting allergy studies listed above.
- Johns Hopkins University · 8 studies
- Johns Hopkins Hospital · 2 studies
- University of Maryland Medical System · 2 studies
- Food Allergy Research & Education
- Institute For Asthma & Allergy
- Johns Hopkins (Site #: 71119)
- Johns Hopkins Medicine
- Johns Hopkins University (Site #: 71119)
What taking part in a allergy study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Common questions
- Are there allergy clinical trials near Washington, D.C.?
- Yes. We're currently tracking 139 recruiting allergy studies with a site near Washington, D.C., each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a allergy study near Washington, D.C.?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Washington, D.C. to take part?
- Not necessarily. These studies have a site near Washington, D.C., but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a allergy trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New allergy studies open near Washington, D.C. regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.